Cystic Fibrosis
Forest Laboratories UK Ltd Submits Marketing Authorisation Application for the First Dry Powder Inhalation Antibiotic for Cystic Fibrosis Patients
Published in Lab Law Weekly, October 2nd, 2009
Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest Laboratories Inc) announced that following the successful completion of its pan-European multi-centre phase III study (the Freedom Study), it has applied to the European Medicines Evaluation Agency (EMEA) to licence its new formulation dry powder colistimethate sodium for inhalation (Colobreathe®) for use by Cystic Fibrosis patients. The new formulation which was wholly developed by Forest Laboratories UK has previously been granted orphan drug status by the European Medicines Evaluation Agency (EMEA) and when approved Colobreathe® will be made available throughout the EU in conjunction with its chosen partner...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2009-10-02)
More Articles from Lab Law Weekly
- Albany Molecular Research, Inc.
AMRI Files New Patent Infringement Lawsuits against Dr. Reddy's Laboratories and Sandoz - Biotechnology Business
Neurocrine Biosciences Secures Committed Equity Financing Facility - Blue Square Israel Ltd
Blue Square Announces it was Served With a Claim and Request for Approval as a Class Action - CEL-SCI Corporation
CEL-SCI Corporation to Raise $20 Million in Registered Direct Offering - Click Forensics, Inc.
Click Forensics Discovers Click Fraud Surge from New Sophisticated "Bahama" Botnet - Clinical Trial Research
Senate Introduces Bill to Boost Participation in Clinical Trials for Rare Diseases - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
